Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

Published Date: 24 Jun 2024

No significant difference between atezolizumab-cabozantinib, docetaxel for OS, PFS, response

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

2.

Year in Review: Non-Small Cell Lung Cancer

3.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

4.

Independent Risk Factors for "Deaths of Despair" Found.

5.

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot